Skip to main content
Search
Main content
Molecular neurodegeneration
Published

Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer's disease genetic pathways

Authors

Bjørn-Eivind Kirsebom, Johanna Nilsson, Ellen Vromen, Peter Mikael Arnesen, Atle Bjørnerud, Ann Brinkmalm, Geir Bråthen, Gøril Rolfseng Grøntvedt, Jonas Jarholm, Kaja Nordengen, Lene Pålhaugen, Per Selnes, Nikias Siafarikas, Ragnhild Eide Skogseth, Sandra Tecelão, Knut Waterloo, Panpan You, Henrik Zetterberg, Dag Aarsland, Betty Tijms, Pieter Jelle Visser, Kaj Blennow, Tormod Fladby

Abstract

Mol Neurodegener. 2025 Oct 13;20(1):107. doi: 10.1186/s13024-025-00899-w.

ABSTRACT

BACKGROUND: Synapse loss is linked to cognitive symptoms in Alzheimer's Disease (AD) and Cerebrospinal fluid (CSF) synaptic biomarkers may clarify disease heterogeneity and disease mechanisms for progression beyond amyloid (Aβ) and tau pathologies, potentially revealing new drug targets.

METHODS: We used a mass-spectrometry panel of 17 synaptic biomarkers including neuronal pentraxins (NPTXs) linked to glutamatergic signaling, and 14-3-3 proteins linked to tau-pathology and synaptic plasticity. Synapse markers were evaluated in two independent cohorts: Dementia Disease Initiation (DDI) (n = 346) and Amsterdam Dementia Cohort (n = 397), both with cognitive assessments up to 10 years. We used linear regression to compare synapse marker differences between CSF-determined Aβ + cognitively normal (CN) and Mild Cognitive Impairment (MCI) groups, with or without CSF tau pathology (Tau+/-), relative to CN Aβ-/Tau- controls; and associations between synapse markers and medial temporal lobe (MTL) MRI volumetrics in the DDI cohort and with verbal memory in both cohorts. A funneling procedure identified proteins related to Aβ/Tau pathology and memory impairment in both cohorts, which were used to evaluate relations to Aβ/Tau biological progression in the DDI cohort and memory decline in both cohorts. Finally, we explored genetic pathways associated with these synaptic proteins.

RESULTS: In both cohorts, most markers were elevated in Aβ+/Tau + cases compared to controls, particularly 14-3-3ζ/δ. Several proteins were reduced in Aβ+/Tau- cases, especially NPTX-2, while 14-3-3ζ/δ remained elevated. However, the increase in e.g. 14-3-3ζ/δ and reduction in e.g. NPTX2 were more pronounced in patients with MCI than CN cases regardless of tau-pathology, corresponding to verbal memory impairment and MTL atrophy. Elevated baseline 14-3-3ζ/δ and rab GDP Dissociation Inhibitor Alpha (GDI-1) associated with future progression from Aβ+/Tau- to Aβ+/Tau+. Significant associations (all p < 0.001) were found between 14-3-3 protein genes (YWHAZ, YWHAE) and pathways linked to AD, including the p38 MAPK, IGF, PIK3/AKT and between GDI1 and p38 MAPK upstream pathway (p < 0.05) all connected to synaptic plasticity. Correspondingly, a robust 14-3-3ζ/δ association with future memory decline was observed in both cohorts.

CONCLUSIONS: Reduced markers for excitatory signaling in Aβ+/Tau- and increased synaptic plasticity markers in Aβ+/Tau + cases suggest differential but linked processes underlying disease progression and resilience in the groups.

PMID:41084010 | PMC:PMC12519626 | DOI:10.1186/s13024-025-00899-w

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg
Dag Aarsland

Prof Dag Aarsland

UK DRI Affiliate Member

Director of the Centre for Healthy Brain Ageing, King's College London

Prof Dag Aarsland